Seminars in Oncology
Volume 36, Issue 4 , Pages 324-337, August 2009

Sarcomas With Spindle Cell MorphologyDisclosures

  • Paola Collini

      Affiliations

    • Department of Anatomic Pathology, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Poul H.B. Sorensen

      Affiliations

    • Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
    • These authors contributed equally to this work.
  • ,
  • Shreyaskumar Patel

      Affiliations

    • Sarcoma Center, Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • These authors contributed equally to this work.
  • ,
  • Jean-Yves Blay

      Affiliations

    • Centre Leon Berard, Hôpital Edouard Herriot, pav. E and INSERM U590, Lyon, France
    • These authors contributed equally to this work.
  • ,
  • Rolf D. Issels

      Affiliations

    • University Hospital Medical Center Grosshadern, Medical Clinic III, Munich, Germany; and HelmholtzZentrum München, German Research Center for Environmental Health, CCG Hyperthermia, Neuherberg, Germany
    • These authors contributed equally to this work.
  • ,
  • Robert G. Maki

      Affiliations

    • Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
    • These authors contributed equally to this work.
  • ,
  • Mikael Eriksson

      Affiliations

    • Department of Oncology, University Hospital, Lund, Sweden
    • These authors contributed equally to this work.
  • ,
  • Xavier Garcia del Muro

      Affiliations

    • Instituto Catalán de Oncología, Barcelona, Spain
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Xavier Garcia del Muro, MD, Instituto Catalán de Oncología, c/Viladomat 319 Atico 1, Barcelona 08029, Spain

In the days before the term “high-grade undifferentiated pleomorphic sarcoma” came into use, one of the most common sarcoma diagnoses was “malignant fibrous histiocytoma,” and before that, in an era before immunohistochemistry, “fibrosarcoma” was used to describe most sarcomas. “Spindle cell” is a descriptive phrase that denotes the cellular shape of many of the sarcomas encountered in the adult population. As a result, they are usually treated differently from small round cell sarcomas, and have different biological characteristics than those tumors and sarcomas with epithelioid morphology. As a very broad generalization, sarcomas with a spindle cell microscopic morphology occur in adults and are treated primarily with surgery and often adjuvant or neoadjuvant radiation as primary therapy. In comparison to small round cell sarcomas such as Ewing sarcoma, the use of adjuvant chemotherapy remains controversial, and the sensitivity of these tumors to chemotherapy in the metastatic setting is highly variable. In this article, we describe some of the clinical and biological characteristics of this group of sarcomas.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Jean-Yves Blay is supported by CONTICANET Network of Excellence of the 6th FP of the European Commission; Poul H.B. Sorensen has received grants from the Canadian Institutes for Health Research; and Robert G. Maki is supported by Program Project Grant No. P01-CA47179; Cycle for Survival.

Disclosures Jean-Yves Blay: Research support, consulting fees (Pfizer, Novartis, Roche, Glaxo Smith Kline)Robert G. Maki: Research support (Pfizer); honoraria (Ziopharm); testimony (Roche)

PII: S0093-7754(09)00107-9

doi:10.1053/j.seminoncol.2009.06.007

Seminars in Oncology
Volume 36, Issue 4 , Pages 324-337, August 2009